EC Microbiology

Review Article Volume 19 Issue 8 - 2023

Ulcerative Colitis: Prevalence, Etiology, Manifestations, and Management

Ashwaq Hamed Alsahafi1*, Hatim Mohammed Alshammari2, Hassan Ali Alnahwi3, Mansour Said Maskati4, Abdullah Adnan Kamal5, Abdullah Fuad Almahroos3, Turki Mohammed Alamri4, Asma Bashir Kalif6, Manea Saleh Ali Alyami7, Ahmed Othman Albalbisi4 and Faleh Matuq Alnefaie8

1Department Of Endoscopy Unit And Internal Medicine, East Jeddah General Hospital-Jeddah 2College of Medicine, Qassim University-Qassim
3College of Medicine, Medical University of Warsaw, Poland
4College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
5College of Medicine, Taif University, Taif, Saudi Arabia 6College of Medicine, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia 7Department of Internal Medicine, Masaryk University, Czechia 8College of Medicine, Jordan University of Science and Technology, Jordan

*Corresponding Author: Ashwaq Hamed Alsahafi, Department of Endoscopy Unit and Internal Medicine, East Jeddah General Hospital, Jeddah, Saudi Arabia.
Received: November 12, 2020; Published: November 30, 2020




Background: Ulcerative colitis is defined as an inflammatory disease characterized mainly by inflammation of the colonic mucosa that spreads from the rectum. It is also known as a chronic condition that usually includes bloody diarrhea and stomach cramps in the second or third decade of life. The condition may be confined to, or may include, the rectum (proctitis), the rectum and the sigmoid colon (proctosigmoiditis), or the left colon (left colitis), Colon (pancolitis), most or all of it. All the previously mentioned factors contribute to the choice of treatment.

Aim: In this review, we will look into the prevalence, symptoms, etiology and management of ulcerative colitis.

Conclusion: The manifestations of UC range from the typical form with bloody diarrhea to the most uncommon symptoms affecting PNS, CNS and other organs other than the intestine. The best management of UC depends mainly on full understanding of the condition, mainly severity of the condition. The management could be by using medications or surgery based on the condition itself. Final conclusion that UC could be managed if the case was diagnosed correctly and the best regimen of treatment could be chosen.

Keywords: Ulcerative Colitis; Etiology of Ulcerative Colitis; Management of Ulcerative Colitis

  1. Wilks S. “Morbid appearances in the intestine of Miss Bankes”. London Medical Times and Gazette 2 (1859): 264.
  2. Danese S and Fiocchi C. “Ulcerative Colitis”. The New England Journal of Medicine 365.18 (2011): 1713-1725.
  3. Joossens S., et al. “The value of serologic markers in indeterminate colitis: A prospective follow-up study”. Gastroenterology 122 (2002): 1242-1247.
  4. Feuerstein JD and Cheifetz AS. “Ulcerative colitis: epidemiology, diagnosis, and management”. In Mayo Clinic Proceedings 89.11‏1553-1563. :(2014)
  5. Truelove SC and Witts LJ. “Cortisone in ulcerative colitis: preliminary report on therapeutic trial”. British Medical Journal 2 (1954):375-378.
  6. Cima RR and Pemberton JH. “Medical and surgical management of chronic ulcerative colitis”. Archives of Surgery 140.3 (2005): 300-‏310.
  7. Truelove SC and Witts LJ. “Cortisone in ulcerative colitis: preliminary report on therapeutic trial”. British Medical Journal 2 (1954):375-378.
  8. Truelove SC and Witts LJ. “Cortisone in ulcerative colitis: final report on a therapeutic trial”. British Medical Journal 2 (1955): 1041-1048.
  9. Cosnes J., et al. “Epidemiology and natural history of inflammatory bowel diseases”. Gastroenterology 140 (2011): 1785-1794.
  10. American Gastroenterological Association. Chronic intestinal disorders”. In: The Burden of Gastrointestinal Disease. Bethesda, Md: American Gastroenterological Association (2001): 27-40.
  11. Bernstein CN and Shanahan F. “Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases”. Gut 57 (2008): 1185-1191.
  12. Cosnes J., et al. “Epidemiology and natural history of inflammatory bowel diseases”. Gastroenterology 140 (2011): 1785-1794.
  13. Whelan G. “Epidemiology of Inflammatory Bowel Disease”. Medical Clinics of North America 74 (1990): 1-12.
  14. Sandler RS and Eisen GM. “Epidemiology of inflammatory bowel disease”. In: Kirsner JB, edition. Inflammatory Bowel Disease. 5th Philadelphia: W.B. Saunders (2000).
  15. Scheid R and Teich N. “Neurologic manifestations of ulcerative colitis”. European Journal of Neurology 14.5 (2007): 483-493.‏
  16. Di Sabatino A., et al. “Recent advances in understanding ulcerative colitis”. Internal and Emergency Medicine 7.2 (2012): 103-111.‏
  17. Bernstein CN and Shanahan F. “Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases”. Gut 57 (2008): 1185-1191.
  18. Anderson CA., et al. “Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47”. Nature Genetics 43 (2011): 246-252.
  19. UK IBD Genetics Consortium, Barrett JC., et al. “Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region”. Nature Genetics 41 (2009): 1330-1334.
  20. McGovern DP., et al. “Genome-wide association identifies multiple ulcerative colitis susceptibility loci”. Nature Genetics 42 (2010): 332-337.
  21. Sabath E., et al. “Galpha12 regulates protein interactions within the MDCK cell tight junction and inhibits tight-junction assembly”. Journal of Cell Science 121 (2008): 814-824.
  22. Boyko EJ., et al. “Effects of cigarette smoking on the clinical course of ulcerative colitis”. Scandinavian Journal of Gastroenterology 23 (1988): 1147-1152.
  23. Koutroubakis IE., et al. “Role of appendicitis and appendectomy in the pathogenesis of ulcerative colitis: a critical review”. Inflammatory Bowel Diseases 8 (2002): 277-286.
  24. Radford-Smith GL., et al. “Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease”. Gut 51 (2002): 808-813.
  25. Meyer AM., et al. “Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs”. Digestive Diseases and Sciences 51 (2006): 168-172.
  26. Chan SS., et al. “Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study”. Alimentary Pharmacology and Therapeutics 34 (2011): 649-655.
  27. Katschinski B., et al. “Oral contraceptive use and cigarette smoking in Crohn’s disease”. Digestive Diseases and Sciences 38 (1993): 1596-1600.
  28. Di Sabatino A., et al. “New pathogenic paradigms in inflammatory bowel disease”. Inflammatory Bowel Diseases (2011).
  29. Carlson M., et al. “Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis”. Gut 50 (2002): 501-506.
  30. Pender SL and MacDonald TT. “Matrix metalloproteinases and the gut: new roles for old enzymes”. Current Opinion in Pharmacology 4 (2004): 546-550.
  31. Fuss IJ., et al. “Nonclassical CD1drestrictedNK T cells that produce IL-13 characterize an atypicalTh2 response in ulcerative colitis”. Journal of Clinical Investigation 113 (2004): 1490-1497.
  32. Heller F., et al. “Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution”. Gastroenterology129 (2005): 550-564.
  33. Rovedatti L., et al. “Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease”. Gut 58 (2009): 1629-1636.
  34. Di Sabatino A., et al. “New pathogenic paradigms in inflammatory bowel disease”. Inflammatory Bowel Diseases (2011).
  35. Danese S and Fiocchi C. “Ulcerative Colitis”. The New England Journal of Medicine 365.18 (2011): 1713-1725.
  36. Ford AC., et al. “Ulcerative colitis”. British Medical Journal 346 (2013): f432.
  37. Di Sabatino A., et al. “Recent advances in understanding Crohn’s disease”. Internal and Emergency Medicine (2011).
  38. Ford AC., et al. “Ulcerative colitis”. British Medical Journal 346 (2013): f432.
  39. Huang B., et al. “Extraintestinal manifestations of ulcerative colitis”.
  40. Williams H., et al. “Extraintestinal manifestations of inflammatory bowel disease”. Current Gastroenterology Reports 10.6 (2008): 597-605.
  41. Rudwaleit M and Baeten D. “Ankylosing spondylitis and bowel disease”. Best Practice and Research: Clinical Rheumatology 20.3 (2006): 451-471.
  42. Wordsworth P. “Arthritis and inflammatory bowel disease”. Current Rheumatology Reports 2.2 (2000): 87-88.
  43. Konturek SJ., et al. “Brain-gut axis and its role in the control of food intake”. Journal of Physiology and Pharmacology 55 (2004): 137-154.
  44. Derbyshire SW. “A systematic review of neuroimaging data during visceral stimulation”. American Journal of Gastroenterology 98 (2003): 12-20.
  45. Lossos A., et al. “Neurologic aspects of inflammatory bowel disease”. Neurology 45 (1995): 416-421.
  46. Sutherland LR., et al. “5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis”. Gastroenterology 92 (1987): 1894-1898.
  47. Lewis JD. “The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease”. Gastroenterology 140 (2011): 1817-1826.
  48. Itzkowitz SH and Present DH. “Crohn’s and Colitis Foundation of America Colon Cancer in IBDSG (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease”. Inflammatory Bowel Diseases 11 (2005): 314-321.
  49. Flores C and Sassaki LY. “Imunomoduladores”. In: Teixeira FV, Kotze PG, editors. Retocolite ulcerativa: estado atual do tratamento no século 21. Rio de Janeiro: DOC (2013): 51-61.
  50. Misiewicz JJ., et al. “Controlled trial of sulfasalazine in maintenance therapy for ulcerative colitis”. Lancet 285 (1965): 185-188.
  51. Azad Khan AK., et al. “An experiment to determine the active therapeutic moiety of sulphasalazine”. Lancet 2 (1977): 892-895.
  52. Felder JB., et al. “Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: a case-control study”. The American Journal of Gastroenterology 95 (2000): 1949-1954.
  53. Papadakis KA and Targan SR. “Role of cytokines in the pathogenesis of inflammatory bowel disease”. Annual Review of Medicine 51 (2000): 289-298.
  54. Gronemeyer H. “Control of transcription activation by steroid hormone receptors”. The FASEB Journal 6 (1992): 2524-2529.
  55. Cann PA and Holdworth CD. “Systemic absorption from hydrocortisone foam enema in ulcerative colitis”. Lancet 1 (1987): 922-923.
  56. Lennard L. “The clinical pharmacology of 6-mercaptopurine”. European Journal of Clinical Pharmacology 43 (1992): 329-339.
  57. Tiede I., et al. “CD28-induced Rac-GTP activity is the molecular target for azathioprine in primary human CD4+ T lymphocytes: a mechanism for azathioprine mediation in IBD based on induction of T cell apoptosis [abstract]”. Gastroenterology 122 (2002): A14.
  58. Lichtiger S., et al. “Cyclosporin in severe ulcerative colitis refractory to steroid therapy”. The New England Journal of Medicine 330 (1994): 1841-1845.
  59. Sternthal MGJ and Kornbluth A. “Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease [abstract]”. Gastroenterology 110 (1996): A1019.
  60. Nicholls RJ. “Ulcerative colitis–surgical indications and treatment”. Alimentary Pharmacology and Therapeutics 16 (2002): 25-28.‏

Ashwaq Hamed Alsahafi., et al. “Ulcerative Colitis: Prevalence, Etiology, Manifestations, and Management”. EC Microbiology  16.12 (2020): 115-123.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net